top of page

We invite you to engage in an interactive nintely minute roundtable led by EverythingALS consortia of Pharma partners, sensor companies, neurologists, data scientists, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.

 

Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in EverythingALS research, which will be expanded to include analyzing data from wearables and smartphones.

  

As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.         

This is an invite only event.

Hosts & Speakers 

  • LinkedIn
  • icons8-link-60
  • LinkedIn
  • LinkedIn
    • LinkedIn
    • icons8-link-60
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn

    Agenda

    Thursday Sept 25th, 2025

    1:00 - 2:00 PM ET   I   10:00 - 11:00 AM PT

    10 minutes

    10 minutes

    10 minutes

    10 minutes

    10 minutes

    10 minutes

    Highlights and Announcements

    ​​Indu Navar, Founder & CEO, EverythingALS

    James Berry, Chief, Division of ALS and MND, Mass General Brigham

    Opening Keynote

    Hear from a Person Living with ALS

    Breaking News: NIH Grant Award for Spanish Speech Study.

    Multi-Lingual Endpoint Development in collaboration with NSU.

    Dr. Lauren Tabor Gray, PhD, CCC-SLP

    Eduardo Locatelli, MD, MPH

    Nova Southeastern University (NSU) Health Cathy J. Husman ALS Center

          ​

    Takeaways: 2025 EverythingALS Digital Endpoints & Biomarker Summit

    • Embedding Listener’s Effort (LE) as a core endpoint in ALS trials

    • From Insights to Intervention: Bridging digital, circuit, and cell-level collaboration with the Allen Brain Institute

    • Clinical Trial Ready Cohort: “People with ALS” — reducing screening costs and recruitment delays

    END OPEN SESSION

    Consortia Members’ Breakout

    1:40-2:00 PM ET

    Collaboration Highlights

    Digital endpoints → brain/cell integration → trial-ready cohorts: building a care-to-cure flywheel for ALS

    Next steps

    Voting on 2025–2026 priorities and alignment of action items

    Agenda

    Participants

     

    © 2025 by EverythingALS

    EverythingALS is part of Peter Cohen Foundation, a non-profit 501(c)(3), United States. EIN 84-3055901 

    Email: info@everythingals.org

    bottom of page